Duality Biotherapeutics, Inc. (HKG:9606)
Hong Kong · Delayed Price · Currency is HKD 107.20
+3.00 (2.88%)
Nov 10, 2026, 4:08 PM HKT
Duality Biotherapeutics Stock Forecast
Stock Price Forecast
According to 8 analysts polled by S&P Global, Duality Biotherapeutics stock has a consensus rating of "Strong Buy" and an average price target of $394.12. The average 1-year stock price forecast is 267.65% higher than the current stock price, while the lowest is $275.78 (+157.26%) and the highest is $501.77 (+368.07%).
Price Target: $394.12 (+267.65%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Duality Biotherapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Apr '26 | May '26 | Jun '26 | Aug '26 | Sep '26 | Oct '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 6 | 5 | 6 | 6 | 6 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 8 | 7 | 8 | 8 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| CMB International Securities | CMB International Securities | Buy Maintains $284.50 | Buy | Maintains | $284.50 | +165.39% | Oct 29, 2026 |
Unknown Analyst UBS No rating | UBS | Buy Maintains $318.00 | Buy | Maintains | $318.00 | +196.64% | Oct 19, 2026 |
Unknown Analyst SDIC Securities No rating | SDIC Securities | Buy Maintains $250.47 | Buy | Maintains | $250.47 | +133.65% | Sep 4, 2026 |
Unknown Analyst Essence Securities No rating | Essence Securities | Buy Maintains $250.47 | Buy | Maintains | $250.47 | +133.65% | Sep 4, 2026 |
Unknown Analyst Huachuang Securities No rating | Huachuang Securities | Buy Maintains $287.40 | Buy | Maintains | $287.40 | +168.10% | Sep 4, 2026 |
Financial Forecast
Revenue This Year
1.35B
from 1.85B
Decreased by -26.98%
Revenue Next Year
1.35B
from 1.35B
Decreased by -0.27%
EPS This Year
-7.09
from -39.80
EPS Next Year
-7.57
from -7.09
EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is CNY.